Home > News > Industry > Pharma News > Germany Merck sees return...

Germany Merck sees return to organic earnings growth in 2024

By - Ruchika Sharma
Published On 2024-03-07 11:22 GMT   |   Update On 2024-03-20 10:33 GMT

Frankfurt: Merck KGaA forecast a return to modest operating earnings growth this year but only when adjusted for currency headwinds, citing a gradual recovery in demand for specialty materials used to make biotech drugs and semiconductors.In a statement on Thursday, the German group said that 2024 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for...

Login or Register to read the full article
Register Now

Frankfurt: Merck KGaA forecast a return to modest operating earnings growth this year but only when adjusted for currency headwinds, citing a gradual recovery in demand for specialty materials used to make biotech drugs and semiconductors.

In a statement on Thursday, the German group said that 2024 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, would likely see "slight-to-moderate" currency-adjusted growth.
Foreign exchange effects are expected to drag earnings lower by between 1% and 4%, it added.
The Life Science division, which makes gear and substances for biotech labs, will see an "inflection point" during the first half of 2024, as drugmakers put in more orders again.
During the pandemic, makers of drugs and vaccines stocked up on Merck's supplies such as filters and bioreactors, which were repurposed for other medical products after the pandemic.
Germany's Merck also predicted a turning point early during the second half of 2024 for chemicals used in semiconductor manufacturing, where it is among the world's largest suppliers.
It also reported 14.2% lower 2023 adjusted EBITDA at 5.9 billion euros ($6.43 billion), which translates into a currency-adjusted decline of 9%, in line with the average analyst estimate posted on the company's website.
Merck's pharmaceuticals unit said it suffered a major setback in December, when its experimental multiple sclerosis (MS) drug fell through in highly anticipated late-stage trials

Read also: Merck gets positive EMA Committee opinion for Keytruda, chemotherapy combo for Resectable non-small cell lung cancer

Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/merck-kgaa-forecasts-return-organic-earnings-growth-2024-2024-03-07/ 

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

USFDA successfully completes inspection at Indoco API Kilo Lab facility, IAS division with no observations
Lupin bags USFDA nod for Midostaurin Capsules for Leukemia treatment
Takeda Biopharma names Annapurna Das as General Manager for India Operations
CDSCO panel agrees with Sun Pharmaceutical's Phase IV Trial Results of Cephalexin plus Clavulanate Potassium Tablets
Cipla to futher invest up to Rs 26 crore in Achira Labs
Mankind Pharma posts over 65 percent rise in Q4 profit
USFDA grants accelerated approval for Bristol Myers Squibb CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Alonzo Weems to retire as Executive Vice President of Enterprise Risk Management, Chief Ethics and Compliance Officer: Eli Lilly